GT Biopharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-28.4M | $-13.2M | $-7.6M | $-20.9M | $-58.0M | $-28.3M | $-38.6M | $-259.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | $0 | $4.0K | $7.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $432.0K | $230.0K | — | $7.7M | $33.9M | $269.0K | $5.3M | $9.7M |
| Net Cash from Operating Activities | $-12.9M | $-12.9M | $-8.9M | $-15.2M | $-15.6M | $-7.3M | $-3.7M | $-10.7M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $0 | $36.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $12.9M | $-2.0M | $12.1M | $-23.0M | $0 | $200.0K | $-36.0K |
| Financing Activities | ||||||||
| Dividends Paid | $229.0K | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $15.8M | $3.0M | $6.3M | $-224.0K | $42.3M | $12.5M | $3.4M | $10.2M |
| Net Change in Cash | $2.9M | $3.0M | $-4.6M | $-3.3M | $3.7M | $5.3M | $-32.0K | $-516.0K |
| Free Cash Flow | — | — | — | — | — | — | $-3.7M | $-10.7M |